A 24-Week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus.

Trial Profile

A 24-Week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2011

At a glance

  • Drugs Pioglitazone; Tesaglitazar
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms ARMOR
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Nov 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Aug 2006 Status change
    • 04 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top